FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	S IN BENEFICIAL	. OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden

hours per response

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Patel Sanj K				2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [ KNSA ]						(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner				
(Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET					3. Date of Earliest Transaction (Month/Day/Year) 03/04/2019						<u> </u>	Officer (circo title		Other (s below)	·
(Street) HAMIL1 (City)			HM11 (Zip)	4.	If Ame	endment, [	Date o	of Original File	ed (Month/Da	ay/Year)	6. Inc Line	Form fil	ed by One Re	ng (Check App eporting Person nan One Repor	1
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3)  2. Transa Date (Month/E				•		2A. Deemond Execution if any (Month/Da	Date	Code (Ins	on Disposed	(A) o	str. 3, 4 and 5	5. Amoun Securities Beneficia Owned Fo Reported Transacti (Instr. 3 a	s Fo lly (D ollowing (I) on(s)	orm: Direct ) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Execution Date, ar) if any		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e s I (A) sed str.	Expiration Date of: (Month/Day/Year) Un De		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	5)	
Share Option	\$17.92	03/04/2019		A		187,000		(1)	03/03/2029	Class A Common Shares	187,000	\$0	187,000	D	

## **Explanation of Responses:**

1. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.

/s/ Thomas W. Beetham,

03/06/2019 Attorney-in-Fact For Sanj K

**Patel** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.